• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Human tissue intended for transplantation--FDA. Interim rule; opportunity for public comment.

出版信息

Fed Regist. 1993 Dec 14;58(238):65514-21.

PMID:10131341
Abstract

The Food and Drug Administration (FDA) is issuing an interim rule to require certain infectious disease testing, donor screening, and recordkeeping to help prevent the transmission of AIDS and hepatitis through human tissue used in transplantation. The regulations are effective upon publication. FDA is taking this action in response to growing concerns that some human tissue products are being offered for transplantation use without even the minimum donor testing and screening needed to protect recipients against human immunodeficiency virus (HIV) infection and hepatitis infection. The new regulations require all facilities engaged in procurement, processing, storage, or distribution of human tissues intended for transplant to ensure that minimum required infectious disease testing has been performed and that records documenting such testing for each tissue are available for inspection by FDA. The regulations also provide authority for the agency to conduct inspections of such facilities and to detain, recall, or destroy tissue for which appropriate documentation is not available.

摘要

相似文献

1
Human tissue intended for transplantation--FDA. Interim rule; opportunity for public comment.
Fed Regist. 1993 Dec 14;58(238):65514-21.
2
Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Fed Regist. 2001 Jun 11;66(112):31146-65.
3
Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment.人体细胞、组织以及基于细胞和组织的产品;供体筛查与检测及相关标签。临时最终规则;公众评论机会。
Fed Regist. 2005 May 25;70(100):29949-52.
4
Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.血液及血液成分现行良好生产规范;向收货人和输血受血者通报接受感染丙型肝炎病毒风险增加的血液及血液成分(“追溯”)。最终规则。
Fed Regist. 2007 Aug 24;72(164):48765-801.
5
Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.人类细胞、组织以及基于细胞和组织的产品生产机构的现行良好组织规范;检查与执法。最终规则。
Fed Regist. 2004 Nov 24;69(226):68611-88.
6
Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Interim final rule; opportunity for public comment.
Fed Regist. 2004 Jan 27;69(17):3823-6.
7
Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.血液及血液成分现行良好生产规范:向接收有更高感染HIV风险的血液及血液成分的收货人发出通知——美国食品药品监督管理局。最终规则。
Fed Regist. 1996 Sep 9;61(175):47413-23.
8
Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.人用药品和生物制品;认定知情同意不可行或违背接受者的最佳利益;撤销1990年暂行最终规则;制定新的暂行最终规则。卫生与公众服务部食品药品监督管理局。暂行最终规则;公众评议机会。
Fed Regist. 1999 Oct 5;64(192):54180-9.
9
General requirements for blood, blood components, and blood derivatives; donor notification. Final rule.
Fed Regist. 2001 Jun 11;66(112):31165-77.
10
Control of communicable diseases; restrictions on African rodents, prairie dogs, and certain other animals. Interim final rule; opportunity for public comment.
Fed Regist. 2003 Nov 4;68(213):62353-69.

引用本文的文献

1
Allograft for knee ligament surgery: an American perspective.异体移植物在膝关节韧带手术中的应用:美国视角。
Knee Surg Sports Traumatol Arthrosc. 2019 Jun;27(6):1882-1890. doi: 10.1007/s00167-019-05425-2. Epub 2019 Mar 19.
2
Sling and bulking agent placement procedures.吊带和填充剂置入手术
Rev Urol. 2004;6 Suppl 5(Suppl 5):S26-46.
3
Decreasing latitude and increasing regulation in transplantable tissue programs.可移植组织项目中监管力度增强且范围缩小。
AORN J. 2005 Nov;82(5):806, 809-14. doi: 10.1016/s0001-2092(06)60273-1.
4
Regulation of hematopoietic stem cell processing and transplantation.
Int J Hematol. 2002 Apr;75(3):237-45. doi: 10.1007/BF02982036.